Structural basis for activation of CB1 by an endocannabinoid analog

Area of Science:

• Pharmacology
• Structural Biology
• Neuroscience

Background:

• Endocannabinoids (eCBs) are endogenous ligands for the cannabinoid receptor 1 (CB1), a G protein-coupled receptor crucial for numerous physiological processes.
• Understanding eCB-CB1 interactions is vital for developing targeted therapeutics for conditions influenced by this system.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying endocannabinoid interactions with the CB1 receptor.
• To characterize the structural and functional consequences of ligand binding to CB1.

Main Methods:

• Determined the structure of the AMG315-bound CB1 signaling complex, an anandamide analog.
• Employed molecular docking, molecular dynamics simulations, and signaling assays.
• Investigated ligand interactions with key residues like F200(3.36) and W356(6.48) and their impact on receptor function.

Main Results:

• Identified distinct features in the ligand-binding pocket of the AMG315-bound CB1 structure compared to previous reports.
• Demonstrated that ligand interactions with "toggle switch" residues (F200(3.36), W356(6.48)) influence receptor signaling.
• Showed that ligand-induced TM2 rearrangements on the intracellular side are critical for G protein activation efficacy and are unique to CB1.

Conclusions:

• Ligand binding to CB1 involves specific interactions with toggle switch residues and TM2, modulating G protein coupling.
• Intracellular TM2 rearrangements represent a unique CB1 feature exploited by specific allosteric modulators.
• These findings provide a molecular basis for designing novel CB1-targeting drugs.